Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2020; 10(18):8315-8342. doi:10.7150/thno.45922 This issue Cite

Review

Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target

Jin Zhang1, Honggang Xiang1, Jie Liu1, Yi Chen1✉, Rong-Rong He2✉, Bo Liu1✉

1. State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
2. Anti-Stress and Health Research Center, College of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China.

✉ Corresponding authors: Bo Liu (B.L.), E-mail: liubo2400com; Phone: (+86)28-85164063. Rong-Rong He (R.H.) E-mail: rongrongheedu.cn; Phone: (+86)20-85221559. Yi Chen (Y.C.), E-mail: toddychancom; Phone: (+86)28-85164063.

Citation:
Zhang J, Xiang H, Liu J, Chen Y, He RR, Liu B. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics 2020; 10(18):8315-8342. doi:10.7150/thno.45922. https://www.thno.org/v10p8315.htm
Other styles

File import instruction

Abstract

Graphic abstract

Sirtuin 3 (SIRT3) is one of the most prominent deacetylases that can regulate acetylation levels in mitochondria, which are essential for eukaryotic life and inextricably linked to the metabolism of multiple organs. Hitherto, SIRT3 has been substantiated to be involved in almost all aspects of mitochondrial metabolism and homeostasis, protecting mitochondria from a variety of damage. Accumulating evidence has recently documented that SIRT3 is associated with many types of human diseases, including age-related diseases, cancer, heart disease and metabolic diseases, indicating that SIRT3 can be a potential therapeutic target. Here we focus on summarizing the intricate mechanisms of SIRT3 in human diseases, and recent notable advances in the field of small-molecule activators or inhibitors targeting SIRT3 as well as their potential therapeutic applications for future drug discovery.

Keywords: SIRT3, Mitochondrial homeostasis, Age-related disease, Cancer, SIRT3 activator, SIRT3 inhibitor

Citation styles

APA
Zhang, J., Xiang, H., Liu, J., Chen, Y., He, R.R., Liu, B. (2020). Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics, 10(18), 8315-8342. https://doi.org/10.7150/thno.45922.

ACS
Zhang, J.; Xiang, H.; Liu, J.; Chen, Y.; He, R.R.; Liu, B. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics 2020, 10 (18), 8315-8342. DOI: 10.7150/thno.45922.

NLM
Zhang J, Xiang H, Liu J, Chen Y, He RR, Liu B. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics 2020; 10(18):8315-8342. doi:10.7150/thno.45922. https://www.thno.org/v10p8315.htm

CSE
Zhang J, Xiang H, Liu J, Chen Y, He RR, Liu B. 2020. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics. 10(18):8315-8342.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use